A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Trials

Background:

• Valproic acid, a mood stabilizer for bipolar disorder, poses risks of congenital anomalies during pregnancy.
• Valnoctamide, a valproic acid derivative, demonstrated reduced risk of congenital abnormalities in animal studies.
• Evaluating novel treatments for acute manic episodes in bipolar disorder is crucial.

Purpose of the Study:

• To assess the efficacy and safety of valnoctamide monotherapy versus placebo in patients experiencing an acute manic episode.
• To compare valnoctamide's effectiveness against risperidone, an established treatment.

Main Methods:

• A 3-week, double-blind, randomized trial involving 173 patients with acute manic episodes.
• Participants received valnoctamide (1500 mg/d), risperidone (6 mg/d), or placebo.
• The primary outcome measure was the change in Young Mania Rating Scale (YMRS) scores.

Main Results:

• Valnoctamide showed no significant difference from placebo in YMRS, Positive and Negative Syndrome Scale, or CGI-BP scores.
• Risperidone significantly improved CGI-BP severity scores compared to placebo.
• Discontinuation rates were higher in the valnoctamide group, primarily due to lack of efficacy.

Conclusions:

• Valnoctamide, at 1500 mg/d, was well-tolerated but ineffective for treating acute mania symptoms.
• Further research may explore potential differences in biological mechanisms between valproic acid and valnoctamide.